4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)
$6.2000
+0.4200 ( +6.90% ) 1.2M
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Market Data
Open
$6.2000
Previous close
$5.7800
Volume
1.2M
Market cap
$279.68M
Day range
$5.7500 - $6.2950
52 week range
$5.5800 - $36.2500
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | May 20, 2024 |
| 8-k | 8K-related | 13 | May 09, 2024 |
| 10-q | Quarterly Reports | 88 | May 09, 2024 |
| 4 | Insider transactions | 1 | Apr 18, 2024 |
| 4 | Insider transactions | 1 | Mar 29, 2024 |
| 4 | Insider transactions | 1 | Mar 20, 2024 |
| 4 | Insider transactions | 1 | Feb 29, 2024 |
| 10-k | Annual reports | 107 | Feb 29, 2024 |